TransCode Therapeutics IncRNAZ
Price$1.68

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$42.8MTTM through 30 Jun 2026
Free Cash Flow -$22.6MTTM through 30 Jun 2026

Margins

Current

Returns

154.7%ROE
-28.4%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio1.97x
Net Debt-$12.8Mnet cash position
Cash & Equivalents$8.4M

Quality Metrics

Altman Z-Score-1.98
Piotroski F-Score1 / 9
Earnings-Beat Rate50.0%

Multi-Year Trend

Diluted EPS
'20'21'22'23'24'25
FY2025: $-50.25

Dividend

No dividend

Capital Allocation

R&D Spend$17.4M

Segment Performance

SegmentRevenueYoYOutlook
RNA Oncology Therapeutics$0
View details

Focusing on clinical proof of concept and seeking strategic licensing partnerships for the broader platform.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.